Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Fibroblast growth factor 23 (FGF23) is known to cause left ventricular hypertrophy (LVH), but controversy exists concerning its effect in dialysis. This study evaluated associations between FGF23 levels, echocardiography and prognosis in patients on hemodialysis (HD).

METHODS: Patients >18 years on chronic HD were included in this cross-sectional study. Plasma C-terminal FGF23 concentration was measured with ELISA and transthoracic echocardiography was performed, both before and after HD treatment.

RESULTS: 239 haemodialysis (HD) patients were included in the study. The FGF23 was median 3560RU/ml (IQR 1447-9952). The mean left ventricular mass index (LVMI) was 110.2±26.7g/m2 and the left ventricular ejection fraction (LVEF) was 52.7±9.9%. Defined by LVMI, LVH was found in 110 patients (46%), of which 92 (84%) had hypertension (p<0.01). Patients with LVH had FGF23 levels of 5319 RU/ml (IQR 1858-12,859) and those without 2496 RU/ml (IQR 1141-7028) (p<0.01). FGF23 was significant positive correlated with LVMI (p<0.01), and negatively to LVEF (p<0.01). In a multivariate analysis, FGF23 was correlated with LVEF (p<0.01), but only marginally to LVMI (p<0.01). Cardiovascular events in the follow up period was not correlated with FGF23. Furthermore, FGF23 was independently correlated with overall mortality (p<0.001).

CONCLUSION: FGF23 was positively correlated with LVH and negatively to LVEF. FGF23 was an independent predictor for overall mortality.

Original languageEnglish
JournalNefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
Volume39
Issue number3
Pages (from-to)258-268
Number of pages11
ISSN0211-6995
DOIs
Publication statusPublished - 7 Feb 2019

ID: 58080284